Advances on biomarkers for invasive pulmonary aspergillosis

doi:10.3877/cma.j.issn.1674-1358.2018.06.005

Abstract

Abstract:

Invasive pulmonary aspergillosis (IPA) is an infection that mainly affects immunosuppressive hosts, including hematological patients and stem cell transplant recipients. In the past decade, the number of susceptible people has increased dramatically, and the incidence of IPA diagnosed in non-granulocytopenia patients was 0.33%-5.8%. The prognosis of non-granulocytopenia patients diagnosed as IPA is poor, mainly due to the delayed diagnosis, and the fatality rate is over 80%. IPA is still difficult to diagnose, especially in patients with non-granulocytopenia, the main reason was the lack of specific clinical manifestations, the sensitivity of microorganism and imaging method was low, and it is very difficult to identify infection in colonized bacteria. Therefore, it is necessary to obtain a new specific biomarkers.

Key words: Invasive pulmonary aspergillosis, Diagnosis, Biomarkers

Junchang Zhang, Biao Xu, Yonggang Wang. Advances on biomarkers for invasive pulmonary aspergillosis[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(06): 543-546.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2018.06.005

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2018/V12/I06/543

References 40

[1]	Garcia-Vidal C, Peghin M, Cervera C, et al. Causes of death in a contemporary cohort of patients with invasive aspergillosis[J]. PLoS One,2015,10(3):e0120370.
[2]	Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial[J]. Lancet,2016,387(10020):760-769.
[3]	Bassetti M, Bouza E. Invasive mould infections in the ICU setting: complexities and solutions[J]. J Antimicrob Chemother,2017,72(Suppl 1):i39-i47.
[4]	Kojima R, Tateishi U, Kamietal M, et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant,2005,11(7):506-511.
[5]	Hoenigl M, Prattes J, Spiess B, et al. Performance of galactomannan, beta-D-glucan, aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis[J]. J Clin Microbiol,2014,52(6):2039-2045.
[6]	Racil Z, Kocmanova I, Toskova M, et al. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases the role of factors affecting assay performance[J]. Int J Infect Dis,2011,15(12):e874-e881.
[7]	De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group[J]. Clin Infect Dis,2008,15(12):1813-1821.
[8]	Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis[J]. Clin Infect Dis,2006,42(10):1417-1427.
[9]	Zhou W, Li H, Zhang Y, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis[J]. J Clin Microbiol,2017,55(7):2153-2161.
[10]	Oz Y, Aslan M, Aksit F, et al. The effect of clinical characteristics on the performance of galactomannan and PCR for the diagnosis of invasive aspergillosis in febrile neutropenic patients[J]. Mycoses,2016,59(2):86-92.
[11]	Kovanda LL, Kolamunnage-Dona R, Neely M, et al. Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response[J]. Clin Infect Dis,2017,64(11):1557-1563.
[12]	Russo A, Giuliano S, Vena A, et al. Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?[J]. Diagn Microbiol Infect Dis,2014,80(1):83-86.
[13]	Bergeron A, Porcher R, Menotti J, et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients[J]. J Clin Microbiol,2012,50(3):823-830.
[14]	Koo S, Bryar JM, Baden LR, et al. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis[J]. J Clin Microbiol,2010,48(4):1255-1260.
[15]	Lamoth F. Galactomannan and 1, 3-β-D-glucan testing for the diagnosis of invasive aspergillosis[J]. J Fungi,2016,2(3):E22.
[16]	Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis[J]. PLoS One,2012,7(8):e43347.
[17]	Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients[J]. Clin Infect Dis,2011,52(10):1218-1226.
[18]	Zhang XB, Chen GP, Lin QC, et al. Bronchoalveolar lavage fluid galactomannan detection for diagnosis of invasive pulmonary aspergillosis in chronic obstructive pulmonary disease[J]. Med Mycol,2013,51(7):688-695.
[19]	Prattes J, Koidl C, Eigl S, et al. Bronchoalveolar lavage fluid sample pretreatment with Sputasol 5 significantly reduces galactomannan levels[J]. J Infect,2015,70(5):541-543.
[20]	Park SY, Lee SO, Choi SH, et al. Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis[J]. J Infect,2010,61(6):492-498.
[21]	Zhuang Q, Ma H, Zhang Y, et al. Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis with nonneutropenic patients[J]. Can Respir J,2017,13(11):3685261.
[22]	Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. Beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis[J]. Clin Infect Dis,2011,52(6):750-770.
[23]	Su KC, Chou KT, Hsiao YH, et al. Measuring (1,3)-β-D-glucan in tracheal aspirate, bronchoalveolar lavage fluid, and serum for detection of suspected Candida pneumonia in immunocompromised and critically ill patients: a prospective observational study[J]. BMC Infect Dis,2017,17(1):252.
[24]	Mutschlechner W, Risslegger B, Willinger B, et al. Bronchoalveolar Lavage fluid (1, 3) beta-D-Glucan for the diagnosis of invasive fungal infections in solid organ transplantation: a prospective multicenter study[J]. Transplantation,2015,99(9):e140-e144.
[25]	Theel ES, Jespersen DJ, Iqbal S, et al. Detection of (1, 3)-beta-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts[J]. Mycopathologia,2013,175(1-2):33-41.
[26]	Maertens JA, Blennow O, Duarte RF, et al. The current management landscape: aspergillosis[J]. J Antimicrob Chemother,2016,71(Suppl 2):ii23-ii29.
[27]	Arvanitis M, Ziakas PD, Zacharioudakis IM, et al. PCR in diagnosis of invasive aspergillosis: a Meta-analysis of diagnostic performance[J]. J Clin Microbiol,2014,52(10):3731-3742.
[28]	Springer J, White PL, Hamilton S, et al. Comparison of performance characteristics of Aspergillus PCR in testing a range of blood-based samples in accordance with international methodological recommendations[J]. J Clin Microbiol,2016,54(3):705-711.
[29]	Mengoli C, Cruciani M, Barnes RA, et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis[J]. Lancet Infect Dis,2009,9(2):89-96.
[30]	Imbert S, Gauthier L, Joly I, et al. Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients[J]. Clin Microbiol Infect,2016,22(6):562. e1-e8.
[31]	Wiederhold NP, Thornton CR, Najvar LK, et al. comparison of lateral flow technology and galactomannan and (1, 3)-β-D-glucan assays for detection of invasive pulmonary aspergillosis[J]. Clin Vaccine Immumol,2009,16(12):1844-1846.
[32]	Willinger B, Lackner M, Lass-Florl C, et al. Bronchoalveolar lavage lateral- flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: a semiprospective multicenter study[J]. Transplantation,2014,27;98(8):898-902.
[33]	Eigl S, Prattes J, Lackner M, et al. Multicenter evaluation of a lateral- flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients[J]. Crit Care,2015,19(1):178-187.
[34]	Shen HP, Tang YM, Song H, et al. Efficiency of interleukin 6 and interferon gamma in the differentiation of invasive pulmonary aspergillosis and pneumocystis pneumonia in pediatric oncology patients[J]. Int J Infect Dis,2016,48(7):73-77.
[35]	Heldt S, Eigl S, Prattes J, et al. Levels of interleukin (IL)- 6 and IL- 8 are elevated in serum and bronchoalveolar lavage fluid of haematological patients with invasive pulmonary aspergillosis[J]. Mycoses,2017,60(12):818-825.
[36]	Sendid B, Poissy J, Francois N, et al. Preliminary evidence for a serum disaccharide signature of invasive Candida albicans infection detected by MALDI mass spectrometry[J]. Clin Microbiol Infect,2015,21(1):88. e1-e6.
[37]	Mery A, Sendid B, Francois N, et al. Application of mass spectrometry technology to early diagnosis of invasive fungal infections[J]. J Clin Microbiol,2016,54(11):2786-2797.
[38]	Koo S, Thomas HR, Daniels SD, et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis[J]. Clin Infect Dis,2014,59(12):1733-1740.
[39]	Vidal-Garcia M, Domingo MP, De Rueda B, et al. Clinical validity of bis(methylthio)gliotoxin for the diagnosis of invasive aspergillosis[J]. Appl Microbiol Biotechnol,2016,100(5):2327-2334.
[40]	Bassetti M, Peghin M, Vena A. Challenges and solution of invasive Aspergillosis in non-neutropenic patients: a review[J]. Infect Dis Ther,2018,7(1):17-27.

Please choose a citation manager

Content to export